Answers are grounded in this paper and cite their sources.
SAINT, an accelerated, high-dose, iTBS protocol with fcMRI-guided targeting, was well tolerated and safe. Double-blinded sham-controlled trials are needed to confirm the remission rate observed in this initial study.
No takes yet. Share an insight, caveat, or question.
Cole et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: